X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (74) 74
index medicus (58) 58
hematology (52) 52
female (48) 48
male (48) 48
oncology (48) 48
middle aged (43) 43
aged (42) 42
adult (33) 33
aged, 80 and over (26) 26
rituximab (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
cancer (19) 19
chemotherapy (18) 18
myelodysplastic syndromes (18) 18
myelodysplastic syndromes - drug therapy (18) 18
treatment outcome (17) 17
prognosis (14) 14
leukemia (13) 13
risk factors (13) 13
survival (13) 13
therapy (13) 13
disease-free survival (12) 12
follicular lymphoma (12) 12
hematology, oncology and palliative medicine (12) 12
non-hodgkins-lymphoma (12) 12
quality of life (12) 12
risk (12) 12
kaplan-meier estimate (11) 11
lymphoma (11) 11
myelodysplastic syndromes - pathology (11) 11
care and treatment (10) 10
lymphomas (9) 9
myelodysplastic syndrome (9) 9
remission induction (9) 9
survival rate (9) 9
acute myeloid-leukemia (8) 8
anemia (8) 8
drug administration schedule (8) 8
follow-up studies (8) 8
lymphoma, follicular - drug therapy (8) 8
mds (8) 8
myelodysplastic syndromes - mortality (8) 8
myelodysplastic syndromes - therapy (8) 8
quality-of-life (8) 8
scoring system (8) 8
analysis (7) 7
antineoplastic agents - therapeutic use (7) 7
cohort studies (7) 7
cyclophosphamide (7) 7
elderly-patients (7) 7
lymphoma, large b-cell, diffuse - drug therapy (7) 7
prospective studies (7) 7
recurrence (7) 7
research (7) 7
response criteria (7) 7
retrospective studies (7) 7
young adult (7) 7
antibodies, monoclonal, murine-derived - administration & dosage (6) 6
b-cell lymphoma (6) 6
disease progression (6) 6
immunotherapy (6) 6
international working group (6) 6
lymphoma, non-hodgkin - drug therapy (6) 6
myelodysplastic syndromes - diagnosis (6) 6
thalidomide - analogs & derivatives (6) 6
transplantation, autologous (6) 6
trial (6) 6
antibodies, monoclonal, murine-derived (5) 5
antimetabolites, antineoplastic - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
azacitidine - administration & dosage (5) 5
bone marrow - pathology (5) 5
canada (5) 5
chop (5) 5
combined modality therapy (5) 5
comorbidity (5) 5
cyclophosphamide - administration & dosage (5) 5
doxorubicin - therapeutic use (5) 5
impact (5) 5
lenalidomide (5) 5
lymphoma, follicular - pathology (5) 5
lymphoma, follicular - therapy (5) 5
minimal residual disease (5) 5
multivariate analysis (5) 5
myelodysplastic syndromes - epidemiology (5) 5
myelodysplastic syndromes - genetics (5) 5
patient outcomes (5) 5
practice guidelines (5) 5
relapse (5) 5
transplantation (5) 5
acute myeloid leukemia (4) 4
adolescent (4) 4
angiogenesis (4) 4
antibodies, monoclonal, murine-derived - therapeutic use (4) 4
antineoplastic agents - adverse effects (4) 4
azacitidine - therapeutic use (4) 4
blood (4) 4
bone-marrow transplantation (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Transfusion, ISSN 0041-1132, 06/2019, Volume 59, Issue 6, pp. 1887 - 1890
Journal Article
Transfusion, ISSN 0041-1132, 06/2019, Volume 59, Issue 6, pp. 1887 - 1890
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2670 - 2677
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 5630 - 5630
Abstract Background Dyslipidemia and metabolic syndrome are risk factors for cancer, and clinically aggressive CLL cells are believed to rely on lipid... 
Journal Article
British Journal of Haematology, ISSN 0007-1048, 12/2014, Volume 167, Issue 5, pp. 626 - 638
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 2806 - 2806
Abstract Background Thrombocytopenia is a common (40-65%) manifestation of MDS. The incidence of bleeding ranges from 3% to 56% encompassing minor bleeds such... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 834 - 834
Abstract Background: Azacitidine (AZA) use in higher-risk MDS has been adopted because it improves survival. Despite this, "real-world" data on the economic... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1700 - 1700
Abstract Despite advances in treatment for diffuse large B cell lymphoma (DLBCL), approximately one third of patients will relapse, with known risk factors... 
Journal Article
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting, 2016, Volume 35, pp. e337 - e344
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2017, Volume 179, Issue 1, pp. 83 - 97
Journal Article